Research

Phase 3, Multicenter Open-label Extension Study to Evaluate the Safety of BOTOX®

(Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence.

A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies.

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence

A Pilot Study to Evaluate Safety and Effectiveness of Poly-l-lactic acid (PLLA) for the Improvement in Appearance of Cellulite.

A Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results with Restylane (CHEEKY Study)

A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study to evaluate effectiveness and safety of GP0109 for augmentation and correction of retrusion in the chin region

A Phase 2, Multicenter, Open Label Study to evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection (DAXI  for Injection) for the combined Treatment of Upper Facial Lines (Glabellar Lines, Dynamic Forehead Lines and Lateral Canthal Lines)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines

A Multicenter, Long-term, Open-label Study to Evaluate the Safety of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines and Lateral Canthal Lines

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence Protocol

Canada Global HARMONY: Prospective, Multi-site, Study to Evaluate Subject Satisfaction with Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment

MT10109L-005 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines

Protocol 1620303 An open-label, multi-center trial to assess the safety of single and repeat treatment of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar lines (SAKURA open-label safety)

Protocol CMO-US-FAS-0486 Histological and Microbiological Evaluation of Late Occurring Nodules with Hyaluronic Acid Dermal Fillers

A Phase 2, Randomized, Double-Blind, Dose Ranging, Active and Placebo Controlled, Multi-Center Study to Evaluate the Safety and Efficacy and Duration of Effect of RT002, a Botulinum Toxin Type A for Injection, to Treat Glabellar Lines.
Completed 2015

91622-130 Phase 2 study to evaluate the safety and efficacy of a range of doses of BOTOX for the treatment of subjects with bilateral masseter muscle hypertrophy (MMH)

ATX-101-13-35: A Multicenter, Double-blind, Non-treatment, Long-term Follow-up Study of Subjects who Completed the ATX-101 (Deoxycholic Acid Injection) Clinical Trials ATX-101-11-22 or ATX-101-11-23 for the Reduction of Localized Subcutaneous fat in the Submental Area.

Protocol: 192024-043: Bimatoprost for the Treatment of Eyebrow Hypotrichosis

BELKYRA for Submental Fat (FDA Approved)
Protocol ATX-101-11-22: Multicenter, randomized, double-blind, placebo-controlled Phase 3 study of ATX-101 (sodium deoxycholate injection) versus placebo for the reduction of localized subcutaneous fat in the submental area.
Completed September 2013

GMA-BTXC-11-004: Long-Term Safety and Patient Satisfaction of Effectiveness of Facial Aesthetic Treatment with BOTOX®; A 10 Year International Experience.
Completed March 2013

Protocol: GMA-BTXC-10-002: A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group, Single Treatment Cycle Study of BOTOX® Cosmetic (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Forehead and Glabellar Rhytides.

Voluma-002: A Multicenter, Single-blind, Randomized, “no-treatment” Control Study of the safety and Effectiveness of JUVÉDERM® VOLUMA XC Injection Gel for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-Face

Protocol: 191622/099:A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Subjects with Facial Rhytides (Crow’s Feet Lines and Glabellar Lines)

CDC 08-01: A Single Centre Controlled Comparison Study to Evaluate the Safety of Lidocaine 15% and Prilocaine 5% Topical Ointment used as Anaesthesia for Intense Pulsed Light Treatments.

Protocol:192024-032-00: A Multicenter, Double-Masked, Randomized, Parallel Study Assessing the Safety and Efficacy of Once-Daily Application of Bimatoprost Solution Compared to Vehicle in Increasing Overall Eyelash Prominence

No. 191622-075-00: A Multicenter, Open-Label Study of the Safety and Efficacy of Repeated Treatments with BOTOX (Botulinum Toxin Type A) for Primary Axillary Hyperhidrosis in Adolescents

Protocol # 60201-0527/1: A prospective, randomized, double-blind, placebo-controlled, multicenter trial to determine the optimal dose of NT 201, free of complexing proteins, in the treatment of glabellar frown lines.

A Clinical Trial to determine the safety and effectiveness of microdroplet injections of SilSkin Silicone oil for HIV associated facial lipoatrophy.

Protocol No. BTX 9920, A Single Center, Pilot, Dose-Comparison Study of Safety and Efficacy of BOTOX Cosmetic (Botulinum Toxin Type A) in Female Subjects with Upper Face Rhytids

Protocol No. BTX 9917, A Long Term Safety Review of Subjects Treated with BOTOX (Botulinum Toxin Type A) for Cosmetic Use.

A multicentre, double-blind, randomized, placebo-controlled, parallel study of the safety and efficacy of repeated treatment with one or two doses of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Primary Axillary Hyperhidrosis Protocol No. 19162-016.

A prospective, double blind randomized, parallel group study analyzing the effect of varying BOTOX dilution in female subjects with glabellar rhytids.

A prospective, double blind randomized, parallel group, dose-ranging study of BOTOX in female subjects with horizontal forehead rhytids

A prospective, double blind, randomized parallel group, dose-ranging study of BOTOX in female subjects with glabellar rhytids.